The impact of SARS-CoV-2 vaccination on Alpha & Delta variant transmission

David W Eyre[1,2], Donald Taylor[3], Mark Purver[3], David Chapman[4], Tom Fowler[3,5], Koen B Pouwels[2,6], A Sarah Walker[2,7], Tim EA Peto[2,7]

[1]Big Data Institute, Nuffield Department of Population Health, University of Oxford, Oxford, UK

[2]NIHR Health Protection Research Unit in in Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford, Oxford, UK

[3]Department of Health and Social Care, UK Government, London, UK

[4]Deloitte MCS Ltd, London, UK

[5]William Harvey Research Institute, Queen Mary University of London, London UK

[6]Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK

[7]Nuffield Department of Medicine, University of Oxford

Abstract

Background

Pre-Delta, vaccination reduced transmission of SARS-CoV-2 from individuals infected despite vaccination, potentially via reducing viral loads. While vaccination still lowers the risk of infection, similar viral loads in vaccinated and unvaccinated individuals infected with Delta question how much vaccination prevents onward transmission.

Methods

We performed a retrospective observational cohort study of contacts of SARS-CoV-2-infected index cases using contact testing data from England. We used multivariable logistic regression to investigate the impact of index case and contact vaccination on transmission, and how this varies with Alpha and Delta variants (classified using S-gene detection/calendar trends) and time since second vaccination.

Results

51,798/139,164(37.2%) contacts tested were PCR-positive. Two doses of BNT162b2 or ChAdOx1 vaccines in Alpha variant index cases independently reduced PCR-positivity in contacts (aOR, adjusted odds ratio vs. unvaccinated=0.18[95%CI 0.12-0.29] and 0.37[0.22-0.63] respectively). The Delta variant attenuated vaccine-associated reductions in transmission: two BNT162b2 doses reduced Delta transmission (aOR=0.35[0.26-0.48]), more than ChAdOx1 (aOR=0.64[0.57-0.72]; heterogeneity p<0.001). Variation in viral load (Ct values) explained only a modest proportion of vaccine-associated transmission reductions.

Transmission reductions declined over time since second vaccination, for Delta reaching

similar levels to unvaccinated individuals by 12 weeks for ChAdOx1 and attenuating

substantially for BNT162b2. Protection from vaccination in contacts also declined in the 3

months after second vaccination.

Conclusions

Vaccination reduces transmission of Delta, but by less than the Alpha variant. The impact of

vaccination decreased over time. Factors other than PCR-measured viral load are important

in vaccine-associated transmission reductions. Booster vaccinations may help control

transmission together with preventing infections.

Introduction

SARS-CoV-2 vaccines have been shown in randomised controlled trials[1–3] and real-world population studies[4,5] to prevent infection and adverse outcomes from several SARS-CoV-2 variants including Alpha (B.1.1.7) and Delta (B.1.617.2).[6–8]

Vaccination also potentially prevents onward transmission by at least two mechanisms. Firstly, by reducing symptomatic and asymptomatic infections and therefore the number of infectious individuals, and secondly via reduced onward spread from those who become infected despite vaccination. Household studies have demonstrated vaccination reduces onward transmission of the Alpha variant from those infected despite vaccination in the UK,[9] Israel[10,11] and Finland.[12] One hypothesised mechanism is lower viral loads observed in post-vaccination Alpha infections[7,13] compared in unvaccinated individuals, as viral load is associated with the likelihood of infection in contacts.[14,15]

However, viral loads in Delta variant infections occurring after vaccination are similar in vaccinated and unvaccinated individuals,[8,16] although the duration of viral shedding may be reduced.[17,18] This questions whether vaccination can control Delta spread as effectively as Alpha, and whether, with increased transmissibility,[19] this explains the rapid global dissemination of Delta despite rising vaccination coverage.

We use national contact testing data from England to investigate the impact of vaccination on onward transmission of SARS-CoV-2, and how this varies with Alpha and Delta variants

74   and time since second vaccination. We also investigate how much reductions in

75   transmission after vaccination are explained by variation in PCR cycle threshold (Ct) values.

Methods

Setting and variants

We performed a retrospective observational cohort study of contacts of symptomatic and

asymptomatic SARS-CoV-2-infected index cases. Data were obtained from the national

contact tracing and testing service in England, NHS Test and Trace. Contacts were eligible for

inclusion if they accessed NHS Test and Trace PCR testing 1-10 days after the index case's

PCR test (typically following symptoms, but also after positive asymptomatic antigen

screening tests), i.e. including contact pairs where the index case was the most likely source

for any infection in the contact.[15] Only index cases with PCR tests performed by three

national "lighthouse" laboratories (Milton Keynes, Alderley Park, Glasgow) were included, as

these tests used the same standardised workflow and PCR assay (Thermo Fisher TaqPath,

assessing for S gene, N gene and ORF1ab targets). Contacts could be tested by any

community/hospital laboratory reporting results to NHS Test and Trace. Vaccination status

in cases and contacts was obtained from National Immunisation Management Service (see

Supplement).

Contacts of index cases tested between 01-January-2021 and 31-July-2021 were included as

follows. Index cases were classified as the Alpha (B.1.1.7) variant based on S-gene target

failure (SGTF), while this was considered a reliable proxy for Alpha, namely to 06-June-2021

(after which <5% cases had SGTF). From 10-May-2021 national spread of Delta meant that

>98% of sequenced cases were either due to the Alpha or Delta variants,[19] such that we

used detection of S-gene on or after 10-May-2021 as a proxy for Delta (see Supplement).

We restricted our analysis to contacts undergoing testing, excluding untested contacts, to

control as much as possible for biases related to health-seeking behaviour (including

differences before and after vaccination), access to testing, and case ascertainment.[20]

Statistical analysis

We used multivariable logistic regression to investigate how onward transmission, i.e.,

SARS-CoV-2 PCR-positive tests in contacts, varied with index case vaccination status. Index

case vaccination status was defined using administrative classifications as: unvaccinated,

partially vaccinated (from day of first vaccine to 13 days after second vaccine), or fully

vaccinated (≥14 days after second vaccine), further considering whether vaccination was

AstraZeneca ChAdOx1 or Pfizer-BioNTech BNT162b2. We also investigated how onward

transmission varied with Alpha vs. Delta index cases and whether any effects varied by

vaccine by including pre-specified interaction terms. We additionally included a model term

for time since 14 days after second BNT162b2 or ChAdOx1 vaccine to estimate the effect of

time since second vaccine.

We adjusted for the following additional covariates: contact event type; index case factors -

age, sex, and symptom status; contact factors - age, sex, vaccination status and time since

vaccination (as above); local deprivation, local SARS-CoV-2 incidence, and calendar time (to

capture changes in behaviour/social distancing, the likelihood of acquisition from a third

party, population-wide vaccine uptake, and the percentage of unvaccinated people

previously infected) (Table S1). We used natural cubic splines and log transformation to

account for non-linearity and tested for interactions (see Supplement).

We refitted models including index case Ct values to investigate whether the effect of index

case vaccination status was explained by viral load (approximated Ct value[21]).

Ethics

The study was performed as public health surveillance and NHS Test and Trace program

quality assurance, under Section 251 of the NHS Act 2006 with approvals from Public Health

England (PHE), the Department of Health and Social Care and NHS Test and Trace. PHE's

Research Ethics and Governance Group (PHE's Research Ethics Committee) reviewed the

study protocol and confirmed compliance with all regulatory requirements. As no regulatory

or ethical issues were identified, it was agreed that full ethical review was not needed, and

the protocol was approved.

Results

151,821 contacts of 99,597 index cases underwent PCR testing between 02-January-2021

and 02-August-2021. 12,657 contacts were excluded with incomplete data (8.3%, see

Supplement). Of the remaining 139,164 contacts (95,716 index cases), 51,798(37.2%) tested

PCR-positive. The median(IQR)[range] index case and contact ages were 38(26-50)[0-102]

and 38(23-50)[0-104] years respectively. 50,356(53%) index cases and 77,277(56%) contacts

were female (see Table S1-S2 for details by case and contact vaccine status). Contact events

143 were predominantly within households (97,387;70%), but also in household visitors

144 (14,066;10%), at events and activities (14,270;10%) and at work/education (13,441;10%).

146 Index case vaccination and onward transmission

147 27,666/55,977(49%) contacts of unvaccinated index cases tested PCR-positive, as did

148 5,256/14,398(37%) and 9,623/36,085(27%) contacts of partially ChAdOx1 and BNT162b2

149 vaccinated cases, and 7,559/25,422(30%) and 1,694/7,282(23%) contacts of fully ChAdOx1

150 and BNT162b2 vaccinated cases. For index cases vaccinated twice with BNT162b2 or

151 ChAdOx1 the median(IQR) days from second vaccine to an Alpha variant PCR-positive test

152 was 41(26-62) or 27(18-43) respectively and 89(69-110) and 50(34-69) for Delta.

154 In a multivariable model (Tables 1, S4), BNT162b2 vaccination in Alpha variant index cases

155 independently reduced PCR-positive results in contacts, with two doses (aOR, adjusted odds

156 ratio at 14 days post-second vaccine vs. unvaccinated=0.18[95%CI 0.12-0.29]) reducing

157 onward transmission more than one (aOR=0.74[0.70-0.80]). There was weak evidence that

158 ChAdOx1 was less effective than BNT162b2 at preventing transmission after one (aOR vs.

159 unvaccinated=0.82[0.76-0.88], p=0.11 vs BNT162b2) and two doses (aOR=0.37[0.22-0.63],

160 p=0.085 vs BNT162b2).

162 The Delta variant was associated with increased onward transmission vs. Alpha for

163 symptomatic index cases (aOR=1.30[1.10-1.54]) and to a greater extent for asymptomatic

164 index cases (aOR=2.14[1.75-2.60]). Post-second dose vaccine-associated reductions on

165 onward transmission were also attenuated with Delta, for both BNT162b2 by 1.9-fold

166 (aOR=1.93[1.25-2.99]) and ChAdOx1 by 1.7-fold (aOR=1.71[1.01-2.90]). This resulted in two

BNT162b2 doses reducing onward transmission of Delta by a greater extent than ChAdOx1

(aOR=0.35[0.26-0.48] vs aOR=0.64[0.57-0.72], respectively, heterogeneity p<0.001).

Vaccination in contacts

The estimated effect of contact vaccination status does not reflect overall vaccine

effectiveness, as study inclusion was conditional on the contact being tested (typically after

developing symptoms). However, as expected, PCR-positivity was highest in unvaccinated

contacts (34,137/70,370(49%)), followed by those partially vaccinated with ChAdOx1,

(3,401/10,325(33%)) and BNT162b2 (5,809/18,017(32%)); those fully vaccinated with

ChAdOx1 (6,163/27,343(23%)) and BNT162b2 (2,288/13,109(17%)) had the lowest rates. In

a multivariable model (Tables 1, S4), with Alpha contacts fully vaccinated with BNT162b2

had lower rates of PCR-positive tests than ChAdOx1 (aOR at 14 days post second vaccine vs.

unvaccinated=0.06[0.04-0.10] vs. aOR=0.29[0.17-0.49] respectively, heterogeneity p<0.001).

With Delta, more BNT162b2 vaccinated contacts tested PCR-positive than with Alpha, but

there was no evidence that PCR-positivity changed in fully ChAdOx1 vaccinated contacts.

Nevertheless, two doses of BNT162b2 remained more effective against Delta than ChAdOx1

(aOR vs. unvaccinated=0.10[0.08-0.13] vs aOR=0.28[0.25-0.32], respectively, heterogeneity

p<0.001).

Duration of protection and transmission reductions

Vaccine-associated reductions in onward transmission declined over time since second

vaccination in index cases (Figure 1A, Table S4). Independently of contact vaccination status,

for each doubling of weeks since 14 days after second vaccination in index cases, the odds

of a contact testing PCR-positive increased 1.13-fold (95%CI 1.09-1.17) for ChAdOx1 and

1.20-fold (1.10-1.31) for BNT162b2 with no evidence of a difference between vaccines

(p=0.19). There was no evidence that fitting different rates by variant improved model fit.

However, higher probabilities of PCR-positive results in contacts 14 days after second

vaccination for Delta vs. Alpha meant that by 12 weeks post second ChAdOx1 dose there

was no evidence that onward Delta transmission rates differed between those not

vaccinated and those having received two ChAdOx1 doses and the impact of BNT162b2 had

also attenuated substantially.

Although 14 days post second vaccination in contacts, those receiving BNT162b2 vs.

ChAdOx1 were at lower risk of testing positive, the protective effect of vaccination in

contacts waned faster for BNT162b2 than ChAdOx1 (Figure 1B, aOR per doubling of weeks

since 14 days after second vaccination=1.37[95%CI 1.27-1.48] vs. 1.16[1.11-1.21] for

ChAdOx1; heterogeneity p=0.002).

Other transmission risk factors

Multiple other factors were associated with contacts testing positive (Figure 2, Table S4,

Figures S2-S4), including contact event type and index case age, with the highest rates of

PCR-positivity after household contact with index cases aged ≥30 years and the lowest rates

following contact with index cases <20 years at work or education (Figure 2A). Contacts in

their 30s, 40s and 70s had the highest rates of positive tests after household contact, while

contacts in their 20s had the highest rates after contact events outside their own home

(Figure 2B). Contacts of index cases of the opposite sex were more likely to test positive,

except for children where contacts of girls were more likely to test positive (Figure 2C). Male

contacts were more likely than female contacts to be infected outside the home (Figure S2).

Case-contact pairs of similar ages were most likely to test positive, particularly with

increasing age (Figure 2D). Contacts of asymptomatic index cases were less likely to test

positive (aOR for Alpha=0.28[95%CI 0.26-0.30], Delta=0.61[0.50-0.73]) likely related to both

lower viral loads (Figure 3) and symptoms. Contacts living in more deprived areas and areas

with higher SARS-CoV-2 incidence (Figure S3) were more likely to test positive. Positivity

also varied by calendar time (Figure S4).

Extent of vaccine impact on transmission explained by viral load

Consistent with previous reports, vaccination with BNT162b2 or ChAdOx1 was associated

with lower viral loads in Alpha index cases at the time of their positive test, e.g. after two

vaccinations in the presence of symptoms, median Ct values (IQR) were 27.9(19.7-32.8) and

25.5(18.1-33.0) vs. 18.4(15.8-22.8) if unvaccinated. However, Delta variant infections had

similar viral loads independent of vaccination status (Figure 3), and higher viral loads than

Alpha in both symptomatic and asymptomatic infections.

We investigated if adjusting for index case Ct values could explain the attenuated reductions

in onward transmission after vaccination seen with the Delta variant. Estimates, adjusted for

Ct value, of the impact of index case vaccination status and variants showed variation in

measured Ct value accounted for only a modest proportion of the impact of vaccination

overall (Figure 4A). This potentially explains why vaccination still reduces onward

transmission of Delta despite Ct values at the index positive test being similar regardless of

vaccination status. Higher viral loads (lower Ct values) were independently associated with

increased transmission for both Alpha and Delta, but with a greater reduction in

transmission of Alpha vs. Delta at lower viral loads (Figure 4B).

Discussion

Using large-scale contact tracing data, we show that BNT162b2 and ChAdOx1 vaccination

both reduce onward transmission of SARS-CoV-2 from individuals infected despite

vaccination. However, reductions in transmission are lower for both vaccines for the Delta

variant compared to Alpha. Vaccines continue to provide protection against infection with

Delta, but to a lesser degree than with Alpha, particularly considering symptomatic

infections or infections with moderate/high viral loads.[8] Therefore, Delta erodes vaccine-

associated protection against transmission by both making infection more common and

increasing the likelihood of transmission from vaccinated individuals who become infected.

It has been hypothesised that vaccines reduce onward transmission from infected

vaccinated individuals by reducing viral loads, as higher viral loads are associated with

transmission.[14,15] Therefore, it is perhaps surprising we found that most of the effect of

vaccines persisted after adjusting for Ct values, i.e., factors other than PCR-measured viral

load at diagnosis are important in vaccine-associated transmission reductions. The single

measured Ct value only approximates viral load at the time of transmission, as viral loads

are dynamic over time.[22] Hence, observed viral loads may not be representative of viral

loads at transmission, however, the strong relationship between measured Ct values and

risk of onward transmission argues against this[15] (replicated here, Figure 4B). Therefore, it is

possible vaccination acts by facilitating faster clearance of viable infectious virions,[17,18] but

leaving damaged ineffective virions behind that still contain PCR-detectable RNA. This may

mean antigen assays have advantages in predicting the risk of onward transmission in those

vaccinated, but this needs further study.

We found that index cases infected with the Delta variant and vaccinated with BNT162b2

had lower odds of having PCR-positive contacts compared to index cases receiving

ChAdOx1, with potentially insufficient power to resolve differences for Alpha. Contacts

vaccinated twice with BNT162b2 also had lower rates of Alpha and Delta infections than

those vaccinated with ChAdOx1.

Protection against onward transmission waned within 3 months post second vaccination.

For Alpha this still left good levels of protection against transmission, but for Delta this

eroded much of the protection against onward transmission, particularly for ChAdOx1,

which by 3 months post second vaccine had no evidence of difference in transmission

compared to that seen in unvaccinated individuals. "Waning" of protective behaviour over

time may also underlie some of the differences seen, with vaccination facilitating reduced

social distancing and mask wearing. However, reductions in antibody levels[23] and vaccine

effectiveness[8] over time suggest biological explanations for increasing transmission over

time are likely important. Additionally, some of the observed decline may be attributable to

the fact that those clinically vulnerable with weaker immune systems were vaccinated

longer ago. We also find that the probability of a contact testing positive increased with

time since their second vaccination. Although BNT162b2 provided higher levels of

protection for contacts throughout the 3 months post-second vaccine, protection against

infection waned faster for BNT162b2 than ChAdOx1, as also seen in a representative UK

survey.[8]

This study has several limitations. We considered only contacts who underwent PCR testing,

to minimise bias introduced by differences in testing behaviour that may occur for multiple

reasons including vaccination of contacts. This means we cannot estimate secondary attack

rates by case and contact vaccination status, and that absolute protective effects of

vaccination on transmission may be under-estimated as vaccine-protected uninfected

contacts may not have sought testing. Our approach is also not likely to eliminate bias,

particularly if test-seeking behaviour is related to perceived vaccine efficacy, given non-

specificity of many symptoms.[24] We did not have sufficient data to consider the impact of

previous infection status, which is also imperfectly ascertained in national testing programs.

It is likely that part of the explanation for the declines over time in the adjusted probability

of contacts testing positive (Figure S4), is increasing prevalence of prior infection in the

unvaccinated group, along with changes in test seeking behaviour and the incidence of

other infections causing similar symptoms.[25] We also had to use SGTF and time as a proxy

for Alpha vs. Delta infection rather than sequencing, which means some low viral load Delta

infections with SGTF may have been misclassified as Alpha, however we restricted the time

period of our dataset to minimise this. As we considered all PCR results in contacts, not just

those tested with assays including an S-gene target, we could not assess SGTF concordance

as supporting evidence for transmission between case-contact pairs. Finally, we did not

have data to adjust for comorbidities; with clinically vulnerable individuals and healthcare

workers vaccinated earlier, this may have partly impacted some of our findings, particularly

on waning over time and differences by vaccine type.

The Delta variant has spread globally and caused resurgences of infection even in the setting

of high vaccination coverage. Increased onward transmission from individuals who become

infected despite vaccination is an important reason for its spread. Booster vaccination

campaigns being considered and implemented[26] are likely to help control transmission as

well as preventing infections.

314   Data availability

315   Applications to use the data in this study can be made to NHS Digital's Data Access Request

316   Service, please see https://digital.nhs.uk/services/data-access-request-service-dars for more

317   details.

319   Declarations

320   DWE declares lecture fees from Gilead outside the submitted work. No other author has a

321   conflict of interest to declare.

323   Funding

This study was funded by the UK Government's Department of Health and Social Care. This

work was supported by the National Institute for Health Research Health Protection

Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Resistance

at Oxford University in partnership with Public Health England (PHE) (NIHR200915), and the

NIHR Biomedical Research Centre, Oxford. The views expressed in this publication are those

of the authors and not necessarily those of the NHS, the National Institute for Health

References

References

1 Polack FP, Thomas SJ, Kitchin N, *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19

Vaccine. *New Engl J Med* 2020; 383: 2603–15.

2 Voysey M, Clemens SAC, Madhi SA, *et al.* Safety and efficacy of the ChAdOx1 nCoV-19

vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled

trials in Brazil, South Africa, and the UK. *Lancet* 2021; 397: 99–111.

3 Baden LR, Sahly HME, Essink B, *et al.* Efficacy and Safety of the mRNA-1273 SARS-CoV-2

Vaccine. *New Engl J Med* 2020; 384: 403–16.

4 Bernal JL, Andrews N, Gower C, *et al.* Effectiveness of the Pfizer-BioNTech and Oxford-

AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in

older adults in England: test negative case-control study. *Bmj* 2021; 373: n1088.

5 Dagan N, Barda N, Kepten E, *et al.* BNT162b2 mRNA Covid-19 Vaccine in a Nationwide

Mass Vaccination Setting. *New Engl J Med* 2021. DOI:10.1056/nejmoa2101765.

6 Bernal JL, Andrews N, Gower C, *et al.* Effectiveness of Covid-19 Vaccines against the

B.1.617.2 (Delta) Variant. *New Engl J Med* 2021; 385: 585–94.

7 Pritchard E, Matthews PC, Stoesser N, *et al.* Impact of vaccination on new SARS-CoV-2

infections in the United Kingdom. *Nat Med* 2021; 27: 1370–8.

8 Pouwels KB, Pritchard E, Matthews PC, *et al.* Impact of Delta on viral burden and vaccine

effectiveness against new SARS-CoV-2 infections in the UK. *Medrxiv* 2021; :

2021.08.18.21262237.

9 Harris RJ, Hall JA, Zaidi A, Andrews NJ, Dunbar JK, Dabrera G. Effect of Vaccination on

Household Transmission of SARS-CoV-2 in England. *New Engl J Med* 2021; 385: 759–60.

10 Layan M, Gilboa M, Gonen T, *et al.* Impact of BNT162b2 vaccination and isolation on

SARS-CoV-2 transmission in Israeli households: an observational study. *Medrxiv* 2021; :

2021.07.12.21260377.

11 Prunas O, Warren JL, Crawford FW, *et al.* Vaccination with BNT162b2 reduces

transmission of SARS-CoV-2 to household contacts in Israel. *Medrxiv* 2021; :

2021.07.13.21260393.

12 Salo J, Hägg M, Kortelainen M, et al. The indirect effect of mRNA-based Covid-19

vaccination on unvaccinated household members. *Medrxiv* 2021; : 2021.05.27.21257896.

13 Levine-Tiefenbrun M, Yelin I, Katz R, *et al.* Initial report of decreased SARS-CoV-2 viral

load after inoculation with the BNT162b2 vaccine. *Nat Med* 2021; 27: 790–2.

14 Marks M, Millat-Martinez P, Ouchi D, *et al.* Transmission of COVID-19 in 282 clusters in

Catalonia, Spain: a cohort study. *Lancet Infect Dis* 2021; 21: 629–36.

15 Lee LYW, Rozmanowski S, Pang M, *et al.* SARS-CoV-2 infectivity by viral load, S gene

variants and demographic factors and the utility of lateral flow devices to prevent

transmission. *Clin Infect Dis* 2021; : ciab421-.

16 Brown CM, Vostok J, Johnson H, *et al.* Outbreak of SARS-CoV-2 Infections, Including

COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings —

Barnstable County, Massachusetts, July 2021. *Morbidity Mortal Wkly Rep* 2021; 70: 1059–

62.

17 Singanayagam A, Hakki S, Dunning J, *et al.* Community Transmission and Viral Load

Kinetics of SARS-CoV-2 Delta (B.1.617.2)Variant in Vaccinated and Unvaccinated Individuals.

Ssrn Electron J 2021. DOI:10.2139/ssrn.3918287.

18 Chia PY, Ong SWX, Chiew CJ, *et al.* Virological and serological kinetics of SARS-CoV-2

Delta variant vaccine-breakthrough infections: a multi-center cohort study. *Medrxiv* 2021; :

2021.07.28.21261295.

19 Public Health England. SARS-CoV-2 variants of concern and variants under investigation

in England: Technical briefing 21. 2021; published online Aug 20.

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_

data/file/1012644/Technical_Briefing_21.pdf (accessed Sept 2, 2021).

20 Fukushima W, Hirota Y. Basic principles of test-negative design in evaluating influenza

vaccine effectiveness. *Vaccine* 2017; 35: 4796–800.

21 Public Health England. Understanding cycle threshold (Ct) in SARS-CoV-2 RT-PCR. 2020;

published online Oct 1.

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_

data/file/926410/Understanding_Cycle_Threshold__Ct__in_SARS-CoV-2_RT-PCR_.pdf

(accessed Sept 27, 2021).

22 He X, Lau EHY, Wu P, *et al.* Temporal dynamics in viral shedding and transmissibility of

COVID-19. *Nat Med* 2020; 26: 672–5.

23 Wei J, Stoesser N, Matthews PC, *et al.* Antibody responses to SARS-CoV-2 vaccines in

45,965 adults from the general population of the United Kingdom. *Nat Microbiol* 2021; 6:

1140–9.

24 Lewnard JA, Patel MM, Jewell NP, *et al.* Theoretical Framework for Retrospective Studies

of the Effectiveness of SARS-CoV-2 Vaccines. *Epidemiology* 2021; 32: 508–17.

25 Vihta K-D, Pouwels KB, Peto T, *et al.* Symptoms and SARS-CoV-2 positivity in the general

population in the UK. *Medrxiv* 2021; : 2021.08.19.21262231.

26 Bar-On YM, Goldberg Y, Mandel M, *et al.* Protection of BNT162b2 Vaccine Booster

against Covid-19 in Israel. *New Engl J Med* 2021. DOI:10.1056/nejmoa2114255.

Table

	Alpha			Delta			Alpha vs Delta		
Characteristic	aOR	95% CI	p-value	aOR	95% CI	p-value	Interaction OR	95% CI	Interaction p value
Impact on onward transmission: Case vaccination status									
Unvaccinated	—	—	—	—	—	—	—	—	—
Partial ChAdOx1	0.82	0.76, 0.88	<0.001	0.98	0.90, 1.06	0.99	1.20	1.07, 1.34	0.003
Partial BNT162b2	0.74	0.70, 0.80	<0.001	0.87	0.81, 0.94	0.004	1.17	1.06, 1.30	0.009
Full ChAdOx1	0.37	0.22, 0.63	0.002	0.64	0.57, 0.72	<0.001	1.71	1.01, 2.90	0.045
Full BNT162b2	0.18	0.12, 0.29	<0.001	0.35	0.26, 0.48	<0.001	1.93	1.25, 2.99	0.003
Contact vaccination status									
Unvaccinated	—	—	—	—	—	—	—	—	—
Partial ChAdOx1	0.89	0.82, 0.97	0.076	0.54	0.50, 0.58	<0.001	0.60	0.54, 0.67	<0.001
Partial BNT162b2	0.69	0.64, 0.75	<0.001	0.58	0.55, 0.61	<0.001	0.83	0.76, 0.92	<0.001
Full ChAdOx1	0.29	0.17, 0.49	<0.001	0.28	0.25, 0.32	<0.001	0.97	0.57, 1.65	0.91
Full BNT162b2	0.06	0.04, 0.10	<0.001	0.10	0.08, 0.13	<0.001	1.64	1.07, 2.51	0.024

406 **Table 1. Relationship between PCR-positive results in contacts, and index case and contact vaccination status according to Alpha/Delta**

407 **variant in the index case**. Results for those with two vaccine doses are estimated at day 14 post second vaccine, see Figure 3 for trends with

408 time post-second vaccine. aOR, adjusted odds ratio, CI confidence interval. Adjustment made for contact event type; index case factors - age,

409   sex, and symptom status; contact factors - age, sex; local deprivation, local SARS-CoV-2 incidence and calendar time (see Table S4 and Figures

410   S2-S8 for details).

Figures

412
413

Figure 1. Estimated probability of a positive PCR test in contacts by time since second vaccination in index cases (panel A) and in contacts (panel B), variant, and vaccine type.

For panel A estimates are displayed for an unvaccinated contact and for panel B for an unvaccinated index case. The relationships shown also apply to vaccinated contacts and cases, as the underlying odds ratios are independent of contact and case vaccine status respectively, however absolute probabilities differ. The dashed horizontal lines indicate the

probability of a positive-PCR result in an unvaccinated contact of an unvaccinated index

case. The shaded area indicates the 95% confidence interval. Adjustment made for

covariates, set to reference values: contact event type (set to Household or

accommodation); index case factors – age (median), sex (female), and symptom status

(symptomatic); contact factors – age (median), sex (female); local deprivation (median),

local SARS-CoV-2 incidence (median) and calendar time (median).

Figure 2. Estimated probability of a positive PCR test in contacts by contact event type and

index case age (panel A) or contact age (panel B), contact age and case and contact sex

(panel C) and case and contact age (panel D). For each panel all other covariates are set to

reference values for categorical values and median values for continuous variables, i.e.

contact event type set to Household or accommodation; index case factors – age (median),

sex (female), vaccination status (unvaccinated) and symptom status (symptomatic); contact

factors – age (median), sex (female), vaccination status (unvaccinated); local deprivation

(median), local SARS-CoV-2 incidence (median) and calendar time (median). Shaded ribbons

and error bars indicate 95% confidence intervals.

Figure 3. Distribution of viral loads by index case vaccination status, variant, and

symptoms. The solid line in each violin plot indicates the median. See Lee *et al* for details of

equivalent viral loads in copies per ml ($\log_{10}(VL) = 12.0 - 0.328*Ct$).[15]

446 **Figure 4. Extent of vaccine-associated transmission reductions explained by change in**

447 **viral load (Ct values) in index case (panel A) and relationship between Ct values and**

448 **transmission by lineage (panel B).** Adjusted odds ratios are shown in panel A and error bars

449 (panel A) or the shaded ribbon (panel B) indicate the 95% confidence interval.